# EDGAR Filing Document

**Accession Number:** 0001838556
**File Stem:** 0001838556-25-000009
**Filing Date:** 2025-11
**Character Count:** 12407
**Document Hash:** 8415a43836afefc698e08d3b180c8687
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001838556-25-000009.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001838556-25-000009

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pelthos Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001919246
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863335449
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94460
- **FILM NUMBER:** 251484221

**BUSINESS ADDRESS:**
- **STREET 1:** 4020 STIRRUP CREEK DRIVE
- **STREET 2:** SUITE 110
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-908-2422

**MAIL ADDRESS:**
- **STREET 1:** 4020 STIRRUP CREEK DRIVE
- **STREET 2:** SUITE 110
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Channel Therapeutics Corp
- **DATE OF NAME CHANGE:** 20241118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chromocell Therapeutics Corp
- **DATE OF NAME CHANGE:** 20220323
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Murchinson Ltd.
- **CENTRAL INDEX KEY:** 0001838556

**ORGANIZATION NAME:**
- **EIN:** 811321967
- **STATE OF INCORPORATION:** A6

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 145 ADELAIDE STREET WEST
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 4E5
- **BUSINESS PHONE:** (416) 845-0666

**MAIL ADDRESS:**
- **STREET 1:** 145 ADELAIDE STREET WEST
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 4E5

## Ex-1

Exhibit I

JOINT FILING STATEMENT

PURSUANT TO RULE 13D-1(K)(1)

The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Shares of Pelthos Therapeutics Inc. together with any or all amendments thereto, when and if required. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

Dated: November 14, 2025

---

| | |
|:---|:---|
| Murchinson Ltd. | Murchinson Ltd. |
| By: | */s/ Marc Bistricer* |
|  | Marc Bistricer, Chief Executive Officer |
| Marc Bistricer | Marc Bistricer |
| By: | */s/ Marc Bistricer* |
|  | Marc Bistricer, Individually |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Pelthos Therapeutics Inc.

**Title of Class of Securities:** Common Stock, par value $0.0001 per share

**CUSIP Number:** 171126204

**Date of Event Which Requires Filing of this Statement:** 09/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [x] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Murchinson Ltd. | Names of Reporting Persons<br>Murchinson Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Z4 | Citizenship or Place of Organization<br>Z4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>280000 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>280000 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>280000 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>280000 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.1% | Percent of Class Represented by Amount in Row (9)<br>9.1% |
| 12. | Type of Reporting Person (See Instructions)<br>IA, CO | Type of Reporting Person (See Instructions)<br>IA, CO |

---

| 1. | Names of Reporting Persons<br>Marc Bistricer | Names of Reporting Persons<br>Marc Bistricer |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Z4 | Citizenship or Place of Organization<br>Z4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>280000 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>280000 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>280000 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>280000 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.1% | Percent of Class Represented by Amount in Row (9)<br>9.1% |
| 12. | Type of Reporting Person (See Instructions)<br>HC, IN | Type of Reporting Person (See Instructions)<br>HC, IN |

---

**Item 1(a). Name of Issuer:**
Pelthos Therapeutics Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
4020 Stirrup Creek Drive, Suite 110
Durham, North Carolina 27703

**Item 2(a). Name of Person Filing:**
Murchinson Ltd.*
Marc Bistricer*

The foregoing persons are hereinafter sometimes collectively referred to as the (Reporting Persons). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported he

**Item 2(b). Address of Principal Business Office:**
145 Adelaide Street West
Toronto A6, M5H 4E5

**Item 2(c). Citizenship:**
Murchinson Ltd. - Canada
Marc Bistricer - Canada

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**Item 2(e). CUSIP Number:**
171126204

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [x] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Murchinson Ltd. - 280,000*
Marc Bistricer - 280,000*
*The information required by this Item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of each cover page to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on information reported in the Issuers 10Q filed with the U.S. Securities and Exchange Commission on November 13, 2025, that as of September 30, 2025, there were 3,090,729 shares of common stock issued and outstanding (the Shares).
The Shares of the Issuer reported herein are held by one or more funds and accounts (together the Funds) advised or sub-advised by Murchinson Ltd. (the Adviser). The Adviser, in its capacity as the adviser of the Funds, has the power to vote and the power to direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own the Shares reported herein. Marc Bistricer, in his capacity as CEO of the Advisor, may also be deemed to have investment discretion and voting power over the shares held by the Funds. Each of Mr. Bistricer and the Advisor disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting persons pecuniary interest therein.

**(b) Percent of class:**

Murchinson Ltd. - 9.1%
Marc Bistricer - 9.1%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Murchinson Ltd. - 0
Marc Bistricer - 0

**(ii) Shared power to vote or to direct the vote:**

Murchinson Ltd. - 280,000
Marc Bistricer - 280,000

**(iii) Sole power to dispose or to direct the disposition of:**

Murchinson Ltd. - 0
Marc Bistricer - 0

**(iv) Shared power to dispose or to direct the disposition of:**

Murchinson Ltd. - 280,000
Marc Bistricer - 280,000

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to an Ontario Securities Commission Registered Investment Advisor is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Murchinson Ltd.**

**Date:** 11/14/2025

**By:** /s/ Marc Bistricer

**Name & Title:** Marc Bistricer, Chief Executive Officer

**Marc Bistricer**

**Date:** 11/14/2025

**By:** /s/ Marc Bistricer

**Name & Title:** Marc Bistricer, Individually